ONTOLOGY REPORT - ANNOTATIONS
| Term: | daunorubicin |
|
| Accession: | CHEBI:41977
|
browse the term
|
| Definition: | A natural product found in Actinomadura roseola. |
| Synonyms: | exact_synonym: | (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside |
| | related_synonym: | (8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; C27H29NO10; COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O; Daunomycin; InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1; InChIKey=STQGQHZAVUOBTE-VGBVRHCVSA-N; acetyladriamycin; daunorubicinum; leukaemomycin C |
| | alt_id: | CHEBI:23560; CHEBI:41970; CHEBI:4330; CHEBI:65723 |
| | xref_casrn: | 20830-81-3 |
| | xref: | ChEMBL:436913 "ChEMBL COMPOUND"; ChemIDplus:1445583 "Beilstein Registry Number"; ChemIDplus:20830-81-3 "CAS Registry Number"; DrugBank:DB00694 "DrugBank"; KEGG COMPOUND:20830-81-3 "CAS Registry Number"; KEGG COMPOUND:C01907 "KEGG COMPOUND"; LIPID MAPS:LMPK13050002 "LIPID MAPS instance" |
| | xref_mesh: | MESH:D003630 |
| | xref: | PDBeChem:DM1 "PDBeChem"; Wikipedia:Daunorubicin "Wikipedia" |
| | cyclic_relationship: | is_conjugate_base_of CHEBI:64677 |
|
|
daunorubicin
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases uptake |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases transport |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases export |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects transport |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases transport |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects export |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
increases secretion |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases uptake |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
increases secretion |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
multiple interactions |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
increases expression |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Abl1 |
c-abl oncogene 1, non-receptor tyrosine kinase |
|
decreases response to substance |
ISO |
3 |
10,804,594 |
10,907,162 |
RGD:6480464 |
CTD |
| G |
Agrn |
agrin |
|
increases expression |
ISO |
5 |
172,999,420 |
173,020,764 |
RGD:6480464 |
CTD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
increases expression |
EXP |
17 |
40,629,318 |
40,684,982 |
RGD:6480464 |
CTD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
multiple interactions |
EXP |
17 |
40,629,318 |
40,684,982 |
RGD:6480464 |
CTD |
| G |
Akr1a1 |
aldo-keto reductase family 1, member A1 (aldehyde reductase) |
|
increases reduction |
ISO |
5 |
136,920,561 |
136,937,422 |
RGD:6480464 |
CTD |
| G |
Akr1a1 |
aldo-keto reductase family 1, member A1 (aldehyde reductase) |
|
increases metabolic processing |
ISO |
5 |
136,920,561 |
136,937,422 |
RGD:6480464 |
CTD |
| G |
Akr1a1 |
aldo-keto reductase family 1, member A1 (aldehyde reductase) |
|
multiple interactions |
ISO |
5 |
136,920,561 |
136,937,422 |
RGD:6480464 |
CTD |
| G |
Akr1a1 |
aldo-keto reductase family 1, member A1 (aldehyde reductase) |
|
affects metabolic processing |
ISO |
5 |
136,920,561 |
136,937,422 |
RGD:6480464 |
CTD |
| G |
Akr1b1 |
aldo-keto reductase family 1, member B1 (aldose reductase) |
|
increases reduction |
ISO |
4 |
61,645,438 |
61,659,530 |
RGD:6480464 |
CTD |
| G |
Akr1b10 |
aldo-keto reductase family 1, member B10 (aldose reductase) |
|
decreases response to substance |
ISO |
4 |
61,755,871 |
61,771,264 |
RGD:6480464 |
CTD |
| G |
Akr1b10 |
aldo-keto reductase family 1, member B10 (aldose reductase) |
|
multiple interactions |
ISO |
4 |
61,755,871 |
61,771,264 |
RGD:6480464 |
CTD |
| G |
Akr1b10 |
aldo-keto reductase family 1, member B10 (aldose reductase) |
|
increases reduction |
ISO |
4 |
61,755,871 |
61,771,264 |
RGD:6480464 |
CTD |
| G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
|
increases metabolic processing |
ISO |
17 |
77,269,626 |
77,286,521 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases response to substance |
ISO |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Angpt1 |
angiopoietin 1 |
|
decreases expression |
EXP |
7 |
78,195,504 |
78,451,471 |
RGD:6480464 |
CTD |
| G |
Angpt2 |
angiopoietin 2 |
|
increases expression |
EXP |
16 |
75,891,757 |
75,942,255 |
RGD:6480464 |
CTD |
| G |
Ankrd1 |
ankyrin repeat domain 1 |
|
decreases expression |
EXP |
1 |
240,316,123 |
240,324,804 |
RGD:6480464 |
CTD |
| G |
Ano3 |
anoctamin 3 |
|
affects response to substance |
ISO |
3 |
96,123,925 |
96,237,157 |
RGD:6480464 |
CTD |
| G |
Anxa2 |
annexin A2 |
|
decreases expression |
ISO |
8 |
73,897,618 |
73,934,041 |
RGD:6480464 |
CTD |
| G |
Anxa4 |
annexin A4 |
|
increases expression |
ISO |
4 |
120,889,617 |
120,947,662 |
RGD:6480464 |
CTD |
| G |
Apex1 |
APEX nuclease (multifunctional DNA repair enzyme) 1 |
|
multiple interactions |
ISO |
15 |
26,904,124 |
26,906,224 |
RGD:6480464 |
CTD |
| G |
Apob |
apolipoprotein B |
|
increases expression |
EXP |
6 |
31,508,060 |
31,548,083 |
RGD:6480464 |
CTD |
| G |
Apoc3 |
apolipoprotein C-III |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Atm |
ataxia telangiectasia mutated |
|
increases expression |
ISO |
8 |
56,894,746 |
56,996,565 |
RGD:6480464 |
CTD |
| G |
Bard1 |
BRCA1 associated RING domain 1 |
|
affects expression |
ISO |
9 |
70,120,151 |
70,198,591 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases response to substance |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bid |
BH3 interacting domain death agonist |
|
multiple interactions |
ISO |
4 |
157,296,383 |
157,318,481 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cab39 |
calcium binding protein 39 |
|
decreases expression |
ISO |
9 |
84,528,678 |
84,590,375 |
RGD:6480464 |
CTD |
| G |
Cacna1s |
calcium channel, voltage-dependent, L type, alpha 1S subunit |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
affects response to substance |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
increases metabolic processing |
ISO |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
multiple interactions |
ISO |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
decreases metabolic processing |
ISO |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Cbr1 |
carbonyl reductase 1 |
|
increases reduction |
ISO |
11 |
33,787,957 |
33,790,320 |
RGD:6480464 |
CTD |
| G |
Cbr3 |
carbonyl reductase 3 |
|
affects response to substance |
ISO |
11 |
33,913,961 |
33,922,221 |
RGD:6480464 |
CTD |
| G |
Cbr3 |
carbonyl reductase 3 |
|
affects metabolic processing |
ISO |
11 |
33,913,961 |
33,922,221 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
decreases expression |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl4 |
chemokine (C-C motif) ligand 4 |
|
decreases expression |
ISO |
10 |
71,759,643 |
71,761,115 |
RGD:6480464 |
CTD |
| G |
Ccnd3 |
cyclin D3 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ccne1 |
cyclin E1 |
|
affects expression |
ISO |
1 |
90,568,189 |
90,577,426 |
RGD:6480464 |
CTD |
| G |
Ccng2 |
cyclin G2 |
|
increases expression |
ISO |
14 |
16,338,132 |
16,346,628 |
RGD:6480464 |
CTD |
| G |
Cdc25a |
cell division cycle 25A |
|
increases expression |
ISO |
8 |
114,237,704 |
114,255,971 |
RGD:6480464 |
CTD |
| G |
Cdh13 |
cadherin 13 |
|
affects response to substance |
ISO |
19 |
48,507,173 |
49,575,123 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
ISO |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
multiple interactions |
EXP |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
affects expression |
EXP |
4 |
171,841,705 |
171,846,506 |
RGD:6480464 |
CTD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
affects expression |
ISO |
5 |
108,908,749 |
108,916,380 |
RGD:6480464 |
CTD |
| G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
|
increases expression |
ISO |
5 |
108,939,669 |
108,945,293 |
RGD:6480464 |
CTD |
| G |
Ceacam1 |
carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) |
|
increases expression |
ISO |
1 |
80,742,540 |
80,758,943 |
RGD:6480464 |
CTD |
| G |
Cebpz |
CCAAT/enhancer binding protein zeta |
|
decreases expression |
ISO |
6 |
1,698,162 |
1,715,846 |
RGD:6480464 |
CTD |
| G |
Clk2 |
CDC-like kinase 2 |
|
increases expression |
ISO |
2 |
181,244,665 |
181,257,364 |
RGD:6480464 |
CTD |
| G |
Clybl |
citrate lyase beta like |
|
affects response to substance |
ISO |
15 |
107,313,924 |
107,539,458 |
RGD:6480464 |
CTD |
| G |
Cmc2 |
COX assembly mitochondrial protein 2 |
|
affects response to substance |
ISO |
19 |
47,002,952 |
47,028,957 |
RGD:6480464 |
CTD |
| G |
Cmip |
c-Maf-inducing protein |
|
affects response to substance |
ISO |
19 |
47,364,495 |
47,572,096 |
RGD:6480464 |
CTD |
| G |
Cwc27 |
CWC27 spliceosome-associated protein homolog (S. cerevisiae) |
|
affects response to substance |
ISO |
2 |
35,567,205 |
35,825,390 |
RGD:6480464 |
CTD |
| G |
Cyba |
cytochrome b-245, alpha polypeptide |
|
multiple interactions |
EXP |
19 |
52,713,150 |
52,721,609 |
RGD:6480464 |
CTD |
| G |
Cyba |
cytochrome b-245, alpha polypeptide |
|
increases expression |
EXP |
19 |
52,713,150 |
52,721,609 |
RGD:6480464 |
CTD |
| G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
|
affects response to substance |
ISO |
6 |
2,548,224 |
2,553,767 |
RGD:6480464 |
CTD |
| G |
Dffa |
DNA fragmentation factor, alpha subunit |
|
increases degradation |
ISO |
5 |
166,179,130 |
166,192,029 |
RGD:6480464 |
CTD |
| G |
E2f5 |
E2F transcription factor 5 |
|
increases expression |
ISO |
2 |
88,346,236 |
88,361,733 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
increases expression |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Edn1 |
endothelin 1 |
|
multiple interactions |
EXP |
17 |
28,303,886 |
28,309,775 |
RGD:6480464 |
CTD |
| G |
Ednra |
endothelin receptor type A |
|
increases expression |
EXP |
19 |
32,042,366 |
32,108,153 |
RGD:6480464 |
CTD |
| G |
Ednra |
endothelin receptor type A |
|
multiple interactions |
EXP |
19 |
32,042,366 |
32,108,153 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
increases expression |
EXP |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
multiple interactions |
EXP |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Egf |
epidermal growth factor |
|
multiple interactions |
ISO |
2 |
227,103,900 |
227,195,062 |
RGD:6480464 |
CTD |
| G |
Ei24 |
etoposide induced 2.4 |
|
increases expression |
ISO |
8 |
38,028,043 |
38,044,316 |
RGD:6480464 |
CTD |
| G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
increases phosphorylation |
ISO |
16 |
69,110,522 |
69,123,895 |
RGD:6480464 |
CTD |
| G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
|
multiple interactions |
ISO |
16 |
69,110,522 |
69,123,895 |
RGD:6480464 |
CTD |
| G |
Epm2aip1 |
EPM2A (laforin) interacting protein 1 |
|
increases expression |
ISO |
8 |
115,653,794 |
115,656,867 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
multiple interactions |
EXP |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
increases expression |
EXP |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Fdxr |
ferredoxin reductase |
|
increases expression |
ISO |
10 |
105,342,684 |
105,351,374 |
RGD:6480464 |
CTD |
| G |
Gapt |
Grb2-binding adaptor protein, transmembrane |
|
affects response to substance |
ISO |
2 |
41,759,021 |
41,761,323 |
RGD:6480464 |
CTD |
| G |
Gpc5 |
glypican 5 |
|
affects response to substance |
ISO |
15 |
99,917,274 |
101,353,034 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
affects response to substance |
ISO |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Hnrpd |
heterogeneous nuclear ribonucleoprotein D |
|
affects response to substance |
ISO |
14 |
10,917,674 |
10,935,989 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
multiple interactions |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ikbke |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon |
|
affects response to substance |
ISO |
13 |
44,197,625 |
44,222,609 |
RGD:6480464 |
CTD |
| G |
Il6r |
interleukin 6 receptor |
|
decreases expression |
ISO |
2 |
182,078,049 |
182,128,135 |
RGD:6480464 |
CTD |
| G |
Ilkap |
integrin-linked kinase-associated serine/threonine phosphatase |
|
affects response to substance |
ISO |
9 |
90,602,949 |
90,626,753 |
RGD:6480464 |
CTD |
| G |
Inpp4b |
inositol polyphosphate-4-phosphatase, type II |
|
affects response to substance |
ISO |
19 |
27,722,430 |
28,363,639 |
RGD:6480464 |
CTD |
| G |
Krt19 |
keratin 19 |
|
increases expression |
EXP |
10 |
89,080,953 |
89,085,670 |
RGD:6480464 |
CTD |
| G |
Krt8 |
keratin 8 |
|
increases expression |
EXP |
7 |
140,713,902 |
140,721,199 |
RGD:6480464 |
CTD |
| G |
LOC499643 |
similar to hypothetical protein FLJ25371 |
|
affects response to substance |
ISO |
2 |
170,755,542 |
170,870,813 |
RGD:6480464 |
CTD |
| G |
Lsamp |
limbic system-associated membrane protein |
|
affects response to substance |
ISO |
11 |
60,170,406 |
60,870,875 |
RGD:6480464 |
CTD |
| G |
Map1b |
microtubule-associated protein 1B |
|
affects response to substance |
ISO |
2 |
30,415,235 |
30,508,354 |
RGD:6480464 |
CTD |
| G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
|
increases expression |
ISO |
10 |
47,075,270 |
47,096,617 |
RGD:6480464 |
CTD |
| G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
|
decreases expression |
ISO |
1 |
15,205,361 |
15,346,422 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
decreases expression |
ISO |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Mdm4 |
Mdm4 p53 binding protein homolog (mouse) |
|
decreases expression |
ISO |
13 |
45,895,832 |
45,931,421 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
increases expression |
EXP |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
EXP |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
increases phosphorylation |
ISO |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Mtor |
mechanistic target of rapamycin (serine/threonine kinase) |
|
multiple interactions |
ISO |
5 |
165,531,402 |
165,640,899 |
RGD:6480464 |
CTD |
| G |
Ncf2 |
neutrophil cytosolic factor 2 |
|
increases expression |
EXP |
13 |
67,806,516 |
67,834,105 |
RGD:6480464 |
CTD |
| G |
Ncf2 |
neutrophil cytosolic factor 2 |
|
multiple interactions |
EXP |
13 |
67,806,516 |
67,834,105 |
RGD:6480464 |
CTD |
| G |
Nck2 |
NCK adaptor protein 2 |
|
decreases expression |
ISO |
9 |
42,650,261 |
42,776,967 |
RGD:6480464 |
CTD |
| G |
Ngef |
neuronal guanine nucleotide exchange factor |
|
affects response to substance |
ISO |
9 |
86,294,206 |
86,327,765 |
RGD:6480464 |
CTD |
| G |
Nox4 |
NADPH oxidase 4 |
|
increases expression |
EXP |
1 |
143,415,816 |
143,603,554 |
RGD:6480464 |
CTD |
| G |
Nox4 |
NADPH oxidase 4 |
|
multiple interactions |
EXP |
1 |
143,415,816 |
143,603,554 |
RGD:6480464 |
CTD |
| G |
Npc1 |
Niemann-Pick disease, type C1 |
|
multiple interactions |
ISO |
18 |
3,725,415 |
3,777,707 |
RGD:6480464 |
CTD |
| G |
Npc1 |
Niemann-Pick disease, type C1 |
|
affects response to substance |
ISO |
18 |
3,725,415 |
3,777,707 |
RGD:6480464 |
CTD |
| G |
Npc1 |
Niemann-Pick disease, type C1 |
|
increases secretion |
ISO |
18 |
3,725,415 |
3,777,707 |
RGD:6480464 |
CTD |
| G |
Nphs1 |
nephrosis 1, congenital, Finnish type (nephrin) |
|
decreases expression |
EXP |
1 |
85,414,492 |
85,444,233 |
RGD:6480464 |
CTD |
| G |
Nphs1 |
nephrosis 1, congenital, Finnish type (nephrin) |
|
multiple interactions |
EXP |
1 |
85,414,492 |
85,444,233 |
RGD:6480464 |
CTD |
| G |
Nppb |
natriuretic peptide B |
|
decreases expression |
EXP |
5 |
165,062,348 |
165,063,650 |
RGD:6480464 |
CTD |
| G |
Nppb |
natriuretic peptide B |
|
increases expression |
ISO |
5 |
165,062,348 |
165,063,650 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
decreases expression |
ISO |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
decreases activity |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nras |
neuroblastoma ras oncogene |
|
increases expression |
ISO |
2 |
198,292,650 |
198,300,286 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
increases cleavage |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pfkm |
phosphofructokinase, muscle |
|
decreases expression |
EXP |
7 |
136,826,122 |
136,846,040 |
RGD:6480464 |
CTD |
| G |
Pik3r1 |
phosphoinositide-3-kinase, regulatory subunit 1 (alpha) |
|
affects response to substance |
ISO |
2 |
32,602,673 |
32,675,350 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
multiple interactions |
ISO |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Plk3 |
polo-like kinase 3 |
|
increases expression |
ISO |
5 |
137,443,540 |
137,448,715 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
multiple interactions |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
increases expression |
EXP |
4 |
151,492,220 |
151,617,331 |
RGD:6480464 |
CTD |
| G |
Ppp1r13l |
protein phosphatase 1, regulatory subunit 13 like |
|
decreases response to substance |
ISO |
1 |
78,727,071 |
78,896,831 |
RGD:6480464 |
CTD |
| G |
Prc1 |
protein regulator of cytokinesis 1 |
|
decreases expression |
ISO |
1 |
136,112,674 |
136,133,720 |
RGD:6480464 |
CTD |
| G |
Prkcd |
protein kinase C, delta |
|
increases cleavage |
ISO |
16 |
5,954,218 |
5,975,743 |
RGD:6480464 |
CTD |
| G |
Pten |
phosphatase and tensin homolog |
|
increases response to substance |
ISO |
1 |
236,771,027 |
236,837,261 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
increases expression |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ranbp17 |
RAN binding protein 17 |
|
affects response to substance |
ISO |
10 |
18,111,581 |
18,413,103 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
increases expression |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
Rbbp5 |
retinoblastoma binding protein 5 |
|
affects expression |
ISO |
13 |
45,364,906 |
45,391,757 |
RGD:6480464 |
CTD |
| G |
Rbbp6 |
retinoblastoma binding protein 6 |
|
increases expression |
ISO |
1 |
181,818,248 |
181,849,942 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
|
affects expression |
EXP |
18 |
1,391,751 |
1,511,865 |
RGD:6480464 |
CTD |
| G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
|
multiple interactions |
EXP |
18 |
1,391,751 |
1,511,865 |
RGD:6480464 |
CTD |
| G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
|
increases phosphorylation |
ISO |
10 |
76,657,024 |
76,698,088 |
RGD:6480464 |
CTD |
| G |
Rps6kb1 |
ribosomal protein S6 kinase, polypeptide 1 |
|
multiple interactions |
ISO |
10 |
76,657,024 |
76,698,088 |
RGD:6480464 |
CTD |
| G |
Ryr2 |
ryanodine receptor 2, cardiac |
|
multiple interactions |
EXP |
17 |
68,959,042 |
69,544,816 |
RGD:6480464 |
CTD |
| G |
Ryr2 |
ryanodine receptor 2, cardiac |
|
decreases expression |
EXP |
17 |
68,959,042 |
69,544,816 |
RGD:6480464 |
CTD |
| G |
Sdc1 |
syndecan 1 |
|
increases expression |
ISO |
6 |
32,253,352 |
32,275,812 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
decreases expression |
ISO |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
ISO |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
multiple interactions |
ISO |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
decreases secretion |
EXP |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Slc25a4 |
solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
|
decreases expression |
EXP |
16 |
49,353,476 |
49,357,271 |
RGD:6480464 |
CTD |
| G |
Slit3 |
slit homolog 3 (Drosophila) |
|
affects response to substance |
ISO |
10 |
19,983,166 |
20,576,689 |
RGD:6480464 |
CTD |
| G |
Smpd1 |
sphingomyelin phosphodiesterase 1, acid lysosomal |
|
increases expression |
ISO |
1 |
163,278,970 |
163,282,813 |
RGD:6480464 |
CTD |
| G |
Smpd1 |
sphingomyelin phosphodiesterase 1, acid lysosomal |
|
increases activity |
ISO |
1 |
163,278,970 |
163,282,813 |
RGD:6480464 |
CTD |
| G |
Smpd3 |
sphingomyelin phosphodiesterase 3, neutral membrane |
|
increases expression |
ISO |
19 |
36,112,166 |
36,195,564 |
RGD:6480464 |
CTD |
| G |
Smpd3 |
sphingomyelin phosphodiesterase 3, neutral membrane |
|
increases response to substance |
ISO |
19 |
36,112,166 |
36,195,564 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
decreases secretion |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Sp110 |
SP110 nuclear body protein |
|
affects response to substance |
ISO |
9 |
84,258,232 |
84,279,462 |
RGD:6480464 |
CTD |
| G |
Sp3 |
Sp3 transcription factor |
|
increases expression |
ISO |
3 |
55,440,985 |
55,485,768 |
RGD:6480464 |
CTD |
| G |
Tagln3 |
transgelin 3 |
|
affects response to substance |
ISO |
11 |
56,587,304 |
56,600,874 |
RGD:6480464 |
CTD |
| G |
Tap1 |
transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) |
|
increases expression |
ISO |
20 |
4,790,363 |
4,800,730 |
RGD:6480464 |
CTD |
| G |
Tap2 |
transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) |
|
affects response to substance |
ISO |
20 |
4,770,446 |
4,784,488 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
increases expression |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
decreases response to substance |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tm4sf20 |
transmembrane 4 L six family member 20 |
|
affects response to substance |
ISO |
9 |
82,073,815 |
82,087,712 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
multiple interactions |
ISO |
15 |
50,138,439 |
50,163,254 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
multiple interactions |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
| G |
Tnfsf9 |
tumor necrosis factor (ligand) superfamily, member 9 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tnnt2 |
troponin T type 2 (cardiac) |
|
multiple interactions |
EXP |
13 |
48,872,972 |
48,885,815 |
RGD:6480464 |
CTD |
| G |
Tnnt2 |
troponin T type 2 (cardiac) |
|
increases secretion |
EXP |
13 |
48,872,972 |
48,885,815 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases expression |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
increases activity |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tyms |
thymidylate synthetase |
|
affects response to substance |
ISO |
9 |
112,604,912 |
112,617,706 |
RGD:6480464 |
CTD |
| G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
|
decreases expression |
EXP |
17 |
40,429,806 |
40,434,083 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
increases expression |
EXP |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
multiple interactions |
EXP |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
affects response to substance |
ISO |
7 |
136,567,614 |
136,617,280 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
decreases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vim |
vimentin |
|
increases expression |
EXP |
17 |
87,847,280 |
87,855,763 |
RGD:6480464 |
CTD |
| G |
Zbtb20 |
zinc finger and BTB domain containing 20 |
|
affects response to substance |
ISO |
11 |
58,662,837 |
59,399,213 |
RGD:6480464 |
CTD |
Term paths to the root
|